Quantifying Beta‐Galactosylceramide Kinetics in Cerebrospinal Fluid of Healthy Subjects Using Deuterium Labeling by Kanhai, K.M.S. et al.
Citation: Clin Transl Sci (2016) 9, 321–327; doi:10.1111/cts.12424
C© 2016 ASCPT. All rights reserved
ARTICLE
Quantifying Beta-Galactosylceramide Kinetics in
Cerebrospinal Fluid of Healthy Subjects Using Deuterium
Labeling
KMS Kanhai1, SC Goulooze1, J Stevens1, JL Hay1, G Dent2, A Verma2, T Hankemeier3, T de Boer4, H Meijering4, JC Chavez2,
AF Cohen1 and GJ Groeneveld1,∗
Therapeutics promotingmyelin synthesismay enhance recovery in demyelinating diseases, such asmultiple sclerosis.However,
no suitable method exists to quantify myelination. The turnover of galactosylceramide (myelin component) is indicative of
myelination in mice, but its turnover has not been determined in humans. Here, six healthy subjects consumed 120 mL 70%
D2O daily for 70 days to label galactosylceramide. We then used mass spectrometry and compartmental modeling to quantify
the turnover rate of galactosylceramide in cerebrospinal fluid. Maximum deuterium enrichment of body water ranged from
1.5–3.9%, whereas that of galactosylceramide was much lower: 0.05–0.14%. This suggests a slow turnover rate, which was
confirmed by the model-estimated galactosylceramide turnover rate of 0.00168 day−1, which corresponds to a half-life of 413
days. Additional studies in patients with multiple sclerosis are needed to investigate whether galactosylceramide turnover
could be used as an outcome measure in clinical trials with remyelination therapies.
Clin Transl Sci (2016) 9, 321–327; doi:10.1111/cts.12424; published online on 15 October 2016.
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
✔ Human myelin turnover and its breakdown product
β-GalC has not been measured before, it has only been
estimated based on animal turnover. Imaging methods are
not yet accurate enough to determine changes in myelin
turnover.
WHAT QUESTION DID THIS STUDY ADDRESS?
✔ Can we calculate the myelin breakdown product β-GalC
turnover in healthy volunteers by labeling it with deuterium?
WHAT THIS STUDY ADDS TO OUR KNOWLEDGE
✔ We describe a method that is capable of quantifying the
β-GalC in humans andmay be accurate enough tomeasure
change in turnover.
HOW THIS MIGHT CHANGE CLINICAL PHARMACOL-
OGY OR TRANSLATIONAL SCIENCE
✔ This methodmay be able to show effect of remyelinating
therapeutic interventions.
Multiple sclerosis is a highly prevalent inflammatory dis-
ease that affects the central nervous system (CNS), caus-
ing progressive disability. Multiple sclerosis is characterized
by a loss of myelin combined with incomplete remyelina-
tion, leading to a progressive demyelination of nerves in the
CNS. Current treatments for multiple sclerosis are designed
to inhibit the inflammatory component of the disease.1
However, increasing the remyelination process is another
promising strategy, which may improve patient outcome.2
Enhancing remyelination may also be beneficial for other
demyelinating diseases, such as neuromyelitis optica,
Krabbe disease, and metachromatic leucodystrophy.
Because of interest in remyelinating therapies, there is
a need for methodologies that quantify remyelination in a
clinical setting. Unfortunately, no such methodology cur-
rently exists; the use of several imaging techniques has been
explored, but no single technique is sufficiently sensitive,
specific for myelin, and correlated to clinical outcome.3
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An alternative way to assess myelin kinetics would be
to quantify the turnover rate of a relevant myelin com-
ponent. Different components of myelin have a different
turnover rates.4,5 Although there are no lipids that are abso-
lutely specific for myelin, galactosylceramide (a cerebroside,
also known as galactosylcerebroside) is the most typical of
myelin.5 The half-replacement time of galactosylceramide is
94–250 days in adult mice, but has never been determined
in humans.4 In mice, the turnover of galactosylceramide
has been reported to be a good measure of myelination,
whereas several other myelin components correlated poorly
with myelination.6 By quantifying the turnover of galactosyl-
ceramide in humans, a measure for (altered) myelin kinetics
might be obtained.
The ability to monitor demyelination and remyelination
is essential to determine possible therapeutic efficacy of
interventions that enhance remyelination. The imaging tech-
niques that are currently being used to try to quantify this
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process are, however, not sufficiently sensitive or specific.3
The myelin sheath that surrounds most axons in the CNS
is a spiral structure that arises from an extension of the
plasma membrane of oligodendrocytes. The thickness of the
myelin sheath is dynamic and may be modulated.7 Myelin
is composed of 40% water and 60% dry mass. The dry
mass is composed of 70% lipids and 30% proteins; this
high concentration of lipids facilitates the rapid conduction
of action potentials along the nerve fiber. In the adult brain,
the various components of myelin have specific turnover
rates.5 The most specific myelin degradation product is
β-D-galactosylceramide (24:1; β-GalC).5
Stable isotope labeling is commonly used to study the in
vivo kinetics of biomolecules.8–11 This method relies on the
labeling of a precursor and the subsequent quantification of
the labeled target molecule over time. The stable isotope can
be a direct precursor (e.g., a labeled amino acid for incor-
poration into proteins) or a more upstream precursor (e.g.,
deuterated water [D2O] or labeled glucose). Animal studies
have shown that deuterium levels up to 15% are generally
without harmful effects.8,9,12 In humans, continuous adminis-
tration of D2O administration over several months—resulting
in deuterium levels of 1–2% in body water—did not result in
adverse effects.13,14
After the stable isotope has been administered, mass
spectrometry (MS) can be used tomeasure labeling of the tar-
get molecule. This technique separates molecules based on
differences in mass (due to different isotope compositions),
but not chemical structure. The resulting data can then be
interpreted using several methods, for example, mass iso-
topomer distribution analysis, or compartmental modeling of
both the precursor and target molecule.15
Here, we used a 70-day deuterium labeling protocol, com-
bined with MS and compartmental modeling, to estimate the
turnover rate of β-GalC (24:1) in healthy human subjects.
MATERIALS AND METHODS
Prestudy simulation
A prestudy simulation of the expected deuterium enrich-
ment of body water and β-GalC was performed to support
the study design. Assuming a daily body water clearance of
2 L and a total body water volume of 50 L, the half-life of deu-
terium in body water was set to a conservative estimate of
17 days.4,16 Because the turnover rate of β-GalC in humans
is unknown, we used the reported half-life for young adult
mice of 90 days.4 After simulations of different study designs,
a 70-day labeling period with daily consumption of 120 mL
of 70% D2O was selected (Figure 1). With this dosing regi-
men, the peak deuterium fraction in the total body water was
estimated to reach 0.037 at day 70; after the dosing regi-
men ended, this fraction returned to baseline by day 200 (i.e.,
130 days after the last D2O dose). The peak deuterium frac-
tion in β-GalC was expected to reach 0.013 at approximately
30 days after the last D2O dose.
Study design
During the study, the six healthy subjects were instructed to
consume 120 mL of 70% D2O daily for 70 days. Weekly urine
samples were collected and used to measure the percent-
age of D2O in the subject’s total body water. The subjects
Figure 1 Prestudy simulation of the deuterium enrichment of total
body water and β-D-galactosylceramide (β-GalC) after 70 days of
consuming a daily dose of 120 mL of 70% deuterated water (D2O).
The vertical dashed line indicates day 70.
also underwent four lumbar punctures (LPs) for cerebrospinal
fluid (CSF) collection. Blood was collected for safety mea-
surements (routine hematology and chemistry). The LPs and
venous punctures were performed 35, 70, 94, and 167 days
after the start of the study. Because initial results indicated
slower kinetics of β-GalC than expected, the study protocol
was amended to include an additional long-term LP. This LP
was taken at approximately 1.5 (subjects 3–6) or 2.0 (subjects
1 and 2) years after the start of the study.
Subjects
Healthy male or female subjects between 18 and 70 years old
with a body mass index of 18–30 kg/m2 were to be enrolled
after having given written informed consent. The subjects
underwent a full medical screening, including medical his-
tory, a physical examination, blood chemistry, hematology
and virology (hepatitis B, hepatitis C, and human immunod-
eficiency virus), urinalysis, and electrocardiogram to assess
eligibility. Key exclusion criteria were: contraindications for
LP, clinical significant abnormalities during screening, and
regular user of any illicit drugs or history of drug abuse or
a positive drug screen at screening.
Study approval
The study was approved by the Medical Ethics Commit-
tee of the BEBO Foundation (Assen, The Netherlands). The
study was conducted according to the Dutch Act on Medical
Research Involving Human Subjects, and in compliance with
Good Clinical Practice and the Declaration of Helsinki.
Measurement of deuterium enrichment in the total body
water
D2O content in total body water was calculated using a
derivatization reaction with a ketone followed by gas chro-
matography/mass spectroscopy analysis. The deuterium
fraction in the urine sample was calculated using the ratio of
deuterated to nondeuterated forms. Measuring D2O in urine
established it as reliable marker of body water D2O, and was
used in other studies.8,11,17 Urine was used because its col-
lection is least invasive for the participating subjects.
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Measurement of deuterium enrichment of β-GalC
β-GalC was extracted from the CSF using a chloroform-
methanol mixture. After isolation and subsequent
evaporation of the organic layer, an aliquot of the reconsti-
tuted sample was injected into a high-performance liquid
chromatography system (Shimadzu Nexera LC30; ‘s Herto-
genbosch, The Netherlands) equipped with a Kinetic C18
column (100 × 3.0 mm, 2.6 μm; Phenomenex, Utrecht,
The Netherlands) that was kept at ambient temperature.
A gradient elution using 5% acetonitrile/95% water (v/v),
1% formic acid/5% acetonitrile/94% water (v/v/v), and ace-
tonitrile as mobile phase was used to separate the β-GalC
from matrix components and was delivered at a flow rate
of 0.8 mL/min into the electrospray ionization chamber of
the MS. Quantification was achieved with MS–MS detection
in positive ion mode using an AB SCIEX Triple Quad 5500
LC-MS/MS (Nieuwerkerk aan den IJssel, The Netherlands)
equipped with a Turboionspray interface at 650°C. The ion
spray voltage was set at 5,500 V. The source parameters:
curtain gas ion source gas 1 and 2, and collision gas were
set at 30, 40, 60, and 6 psi, respectively. The compound
parameters: the declustering potential, collision energy,
entrance potential, and collision cell exit potential were 121,
129, 10, and 15 V for β-GalC. Detection of the ions was
carried out in the multiple-reaction monitoring mode, by
monitoring the transition pairs of 810.6 → 630.6 amu (M0),
m/z 811.6 → 631.6 (M1), m/z 812.6 → 632.6 (M2), m/z
813.6 → 633.6 (M3), m/z 814.6 → 634.6 (M4), m/z 815.6 →
635.6 M5), m/z 816.6 → 636.6 (M6), … and m/z 819.6 →
639.6 (M9), where Mi is the β-GalC mass isotopomer with
i additional neutrons compared with the mass isotopomer
without any heavy isotope (M0). Quadrupoles Q1 and Q3
were set on unit resolution. The analysis data obtained were
processed by Analyst software version 1.5.2.
The isotopomer data of β-GalC were used to calculate
the change in average number of additional neutrons (the
replacement of a hydrogen atom by a deuterium atom adds
one neutron to β-GalC). This was then divided by the total
number of hydrogen atoms in β-GalC (78) to yield the change
from baseline of the average deuterium fraction of the hydro-
gen atoms in β-GalC.18
Compartmental model
A compartmental model that describes the turnover of body
water (precursor) and β-GalC (product) was fit to the data
using the nonlinear mixed effects modeling program NON-
MEM version 7.3.0.19 The first-order conditional estimation
with interaction method was used to estimate typical param-
eter values and their interindividual variability. The interindi-
vidual variability was only included in the model when it sig-
nificantly (p < 0.05) improved the model fit (minus two times
the log likelihood reported by NONMEM).
The body water turnover was characterized with two struc-
tural parameters: the daily water input/output and the size of
the total body water pool. A theoretical estimate of subjects’
total body water—based on their sex, height, weight, and
age—was used as a covariate for daily water input/output.20
This model described the deuterium enrichment of body
water over time.
Table 1 Subject characteristics
Characteristic Mean (range) or number (%)
Age, y 28.2 (19–67)
Sex
Male 2 (33)
Female 4 (67)
Weight, kg 67.5 (56.8–87.5)
Height, m 1.75 (1.64–1.90)
BMI 21.9 (19.3–25.3)
BMI, body mass index.
The production of β-GalC from the (indirect) precursor
body water was characterized with two structural parame-
ters: fraction of β-GalC with a fast turnover, and the turnover
rate of that fraction. The turnover rate of the remaining frac-
tion of β-GalC (with a slow turnover) was assumed to have
a negligible impact on the β-GalC deuterium enrichment in
this study, and was therefore not estimated (i.e., assumed to
be zero).
RESULTS
Clinical study
Six healthy adult subjects were enrolled in the study; their
demographics are summarized in Table 1. All subjects com-
pleted the study, and all of the reported adverse events were
mild and transient. Most frequent reported adverse events
were headache (14%) and nasopharyngitis (10%). No post-
dural puncture headache occurred. All subjects appeared
to reach steady-state deuterium enrichment in body water
during the 70-day labeling period. There was considerable
interindividual variability in the extent of body water enrich-
ment, with maximum values ranging from 0.015–0.039. Body
water enrichment decreased rapidly after the last D2O dose:
to an average of 16.3% of maximum levels on day 93.
The maximum deuterium enrichment of β-GalC was about
25-fold lower than that of body water and ranged from
0.0005–0.0014. The enrichment of β-GalC decreased slowly:
at day 167, the β-GalC enrichment was still high (92% of
maximum enrichment on average). Even 1.5–2.0 years after
the start of the study, a measurable β-GalC enrichment
above baseline was still present in all subjects (average 41%
of maximum enrichment; see Figure 2).
Compartmental model output
Interindividual variability was only estimated for daily water
input/output; for the other structural parameters, it did not
result in a significantly improved model fit. The interindi-
vidual differences in deuterium enrichment of β-GalC were
attributed exclusively to differences in deuterium enrichment
of body water (precursor). The compartmental model was
used to fit the data, resulting in an adequate characterization
of the deuterium enrichment of both body water and β-GalC
(Figures 3 and 4).
The final model’s parameter estimates and variability are
summarized in Table 2. Al parameters were estimated with
good precision (i.e., low standard errors). The typical values
for the daily water input/output (3.25 L) and the size of the
total body water pool (35.5 L) correspond to a turnover rate
constant of 0.092 or a body water half-life of 7.6 days. The
www.wileyonlinelibrary/cts
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Figure 2 The isotopomers of β-D-galactosylceramide (β-GalC)
and how the relative quantity of each isotopomer changes over
time during and after 10 weeks of deuterated water (D2O) label-
ing. D0 implies that the β-GalC molecule has no extra neutron,
whereas D1, D2, D3, and D4 means that the β-GalC molecule has
1, 2, 3, and 4 extra neutrons, as determined by mass spectrom-
etry. In the baseline sample (pool, day 0) the D1, D2, D3, and D4
isotopomers are also present, which is due to natural occurrence
of stable radioisotopes in food substances (primarily C13).
Table 2 Parameter estimates derived from the final model
Estimate RSE (%)a IIVb
DWI, L·day-1 3.25 6.55 15.5
BW, L 35.5 3.24 NE
Kβ-GALC, day-1 0.00168 8.81 NE
Sβ-GALC 0.379 9.66 NE
Additive errorbody waterc 0.00130 20.5 NA
Additive errorBGalCc 0.000116 19.7 NA
BW, body weight; DWI, daily water intake; NA, not applicable; NE, not esti-
mated; RSE, relative standard error.
aRSE, calculated from NONMEM’s reported standard error.
bCoefficient of variation (%) of interindividual variability.
cResidual variability expressed as SD.
estimated β-GalC turnover rate constant (of the fast fraction)
is much lower: 0.00168, which corresponds to a half-life of
413 days. This slow β-GalC turnover is consistent with its
relatively low, but long-lasting deuterium enrichment.
DISCUSSION
Here, we report that orally administered deuterated water
can be used to label and track the metabolism of β-GalC
in human subjects, and these data can be used to estimate
the turnover rate for this myelin breakdown product. The low,
but long-lasting enrichment shows that β-GalC has a slow
turnover. We used compartmental modeling to characterize
this turnover, as it allowed us to account for differences in
deuterium enrichment of body water between subjects and
within subjects over time. With this empirical model, we esti-
mated a half-life of 413 (352–499) days for β-GalC in CSF.
Importantly, the turnover of β-GalC has been reported for
mice,4 but this has never been reported in human subjects.
An estimated fraction of β-GalC with a fast turnover was
included in the model to accurately describe the β-GalC
enrichment data. Although this factor does not have a direct
physiological meaning, one possible interpretation would be
that β-GalC in CSF is produced from two metabolic com-
partments. One compartment would represent myelin with
a shorter half-life (413 days, as estimated by the model).
The other compartment would turnover even more slowly, to
the extent that the amount of deuterium enrichment present
in its breakdown products after a 70-day labeling period is
negligible. In this interpretation of the empirical model, the
estimated fraction of β-GalC with a fast turnover then rep-
resents the fraction of β-GalC in the CSF that originates
from the compartment with a “fast” turnover. This combina-
tion of fast and slow turnover seems physiologically plausi-
ble, as it has been described for various myelin components
in animals: cholesterol, galactosylceramide, sulfatide, and
phospholipids.4,21 One of several possible interpretations of
these data is that there is a more stable metabolic pool con-
sisting of inner layers of myelin that may be less accessible
for metabolic turnover and that some of the newly formed
myelin remains in outer layers and stays accessible for what-
ever mechanisms are involved in catabolism, thus account-
ing for the rapid turnover of this pool.5
The thickness of the myelin sheath can be modified by
oligodendrocytes, and oligodendrocyte turnover contributes
to myelin remodeling. However, we expect the effect of oligo-
dendrocyte turnover to be minimal as myelination has been
shown to be considerably more dynamic than oligodendro-
cyte generation in human white matter.7 Different myelin
dynamics in different parts of the brain are not taken into
account in our study as we estimated the average β-GalC
turnover.
It is important to realize that the turnover of β-GalC does
not necessarily represent the turnover of myelin. Two scenar-
ios are possible: either the myelin turnover is slower than the
β-GalC turnover and therefore rate limiting, or the β-GalC
turnover is slower than myelin turnover and therefore rate-
limiting. β-GalC kinetics would only be a suitable marker of
myelin turnover if the myelin turnover is slower and there-
fore the rate limiting step. If β-GalC kinetics are rate limit-
ing, it would not be suitable as a marker of myelin kinetics.
We believe it is far more likely, however, that myelin turnover
is rate limiting. First of all, a previous study in mice demon-
strated that labeling of β-GalC with D2O provided a good
proxy marker for myelin turnover.6 Second, most metabolic
processes in the human body have a much faster turnover
than 413 days21–23 and it is therefore far more probable that
the β-GalC turnover that we measure is this slow because
β-GalC is attached to the myelin surrounding nerves, and
nerves are known to have an extremely slow turnover.22 Con-
versely it is unlikely that β-GalC removal from the CSF com-
partment would be rate limiting and, therefore, influence the
slow turnover of β-GalC that we report here. CSF proteins in
general have a residence time in the CSF of hours to days,
maybe some of weeks, but not of months to years.6,23–25 An
average adult human produces approximately 500mL of CSF
per day, which, with an average CSF volume of 150 mL, will
lead to replacement of all circulating CSF more than three
times daily. It would be hard to imagine how any molecule
could reside in the CSF for months without being removed.
It is therefore far more likely that if we measure deuterated
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Figure 3 Individual body water deuterium enrichment profiles and model predictions over time during and following 70 days of oral
deuterated water (D2O) administration. In each panel, the individual observations are represented as blue dots, the population predictions
are represented as a dashed blue line, and the individual prediction is represented as a dashed green line. The vertical dashed line indicates
day 70.
Figure 4 Individual baseline-corrected β-D-galactosylceramide (β-GalC) deuterium enrichment profiles andmodel predictions during and
following 70 days of oral deuterated water (D2O) administration. In each panel, the observations are represented as blue circles, and the
model prediction is shown as a dashed blue line. The vertical dashed line indicates day 70. Baseline samples were healthy volunteer
cerebrospinal fluid (CSF) samples from a biobank. CFBL, change from baseline.
β-GalC in the CSF over a very long period of up to 1.5 years,
that there is a continuous source of shedding of β-GalC into
the CSF from a reservoir, which we know from the literature to
be myelin in the CNS.26 In conclusion, although the turnover
of β-GalC does not necessarily represent the turnover of
myelin,6 β-GalC found in the CSF is most likely produced
by the breakdown of myelin in the CNS, and β-GalC CSF
kinetics therefore likely reflect myelin turnover.
A measurement of the turnover rate of myelin in mice of
various ages revealed that the turnover rate ranged from
94–250 days.4 This rate differs considerably from the rate that
we observed in healthy human subjects. However, such a
www.wileyonlinelibrary/cts
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difference in the rate of ametabolic process between humans
andmice is not unexpected.27–29 For example, previous stud-
ies reported that the overall turnover rate for proteins in
mice is nearly 10-fold higher in mice than in humans.22 The
rate of cholic acid synthesis is 9.3-fold higher in mice than
in humans, and the rate of cholesterol synthesis is 16-fold
higher in mice. These differences are consistent with our
observed difference between mice and humans with respect
to the apparent turnover rate of myelin. Although it is likely
that the turnover of myelin is correlated with age, the rela-
tively low number of subjects in our study precluded the pos-
sibility of drawing anymeaningful conclusions with respect to
the relationship between age and turnover rate.
Here, we used compartmental modeling to accurately
describe deuterium enrichment in body water and labeling of
β-GalC during and after chronic ingestion of deuterium. Our
use of compartmental modeling enabled us to interpret the
isotope labeling data in the absence of steady-state label-
ing of any precursor. This was an important feature of our
study, as the deuterium fraction in body water did not reach
steady-state levels for a significant part of the study duration.
It is also important to note that the model and its estimated
parameters are empirical. As body water is not an immedi-
ate precursor of β-GalC, the apparent myelin turnover rate
constant should not be interpreted as a measure for β-GalC
turnover. Instead, it is a single rate constant for the entire
biochemical pathway between body water and β-GalC in
CSF. As this pathway includes the synthesis and degrada-
tion of myelin, the estimated turnover rate constant of β-GalC
may, however, be suitable as a biomarker for the kinetics of
myelin. Interestingly, the model did not improve upon includ-
ing interindividual variability in the myelin kinetics; correcting
for the individual differences in body water turnover seemed
to explain most of the interindividual variability seen in the
deuterium enrichment of β-GalC as well. This suggests that
the variability in myelin kinetics in healthy human subjects is
modest, although confirmation of this would require a study
with more than six subjects.
The method that we describe here, in which we measured
the deuterium enrichment of β-GalC in the CSF of healthy
human subjects, may be used to test novel therapeutic
interventions designed to enhance remyelination. Currently,
the demyelination and remyelination process is measured
with a magnetic resonance imaging scan. A recent review
evaluated imaging modalities that may be better suited to
measuring myelin content in vivo, including magnetization
transfer ratio, restricted proton fraction f (from quantitative
magnetization transfer measurements), myelin water frac-
tion, diffusion tensor imaging, and positron emission tomog-
raphy imaging.3 Unfortunately, no individual modality pro-
vides sufficient sensitivity or specificity for myelin, nor can
any individual method provide a suitable correlation with clin-
ical features.3 Positron emission tomography imaging using
[11C]PIB and [11C]MeDAS are promising imaging modalities.
However, further studies are needed in order to validate their
use, particularly with respect to the study of multiple scle-
rosis in human patients.3 We therefore suggest that stable
isotope labeling using D2O may be a more useful method for
measuring demyelination and remyelination. Drugs that can
increase remyelination are currently being developed. There-
fore, a method for quantifying remyelination is essential in
order to determine the efficacy of such drugs. In this respect,
we suggest that our method for measuring myelin kinet-
ics may provide superior results compared with the imaging
modalities that are currently available.
In a proof-of-concept study with a compound that is
expected to enhance remyelination, it may not be neces-
sary to follow-up subjects for the same 1.5–2.0-year period
of this study. This is because peak β-GalC enrichment is
probably more indicative of myelination than the elimination
phase of β-GalC. Therefore, there would be no need to mea-
sure long-term elimination of deuterium from β-GalC. This
could shorten the study duration to as little as 15 weeks:
10 weeks of deuterium labeling and 5 weeks of washout
to allow β-GalC to reach peak enrichment. Five weeks is
approximately five times the calculated half-life of D2O dis-
appearance from body water. In the absence of ongoing D2O
labeling, deuterium-enrichment of the β-GalC cannot further
increase when D2O has been washed-out from body water.
In this study, we developed a safe methodology to mea-
sure the turnover rate of the myelin component β-GalC in
humans, which is likely indicative of myelination. Additional
studies in patients with multiple sclerosis are needed to vali-
date this method as an outcomemeasure in clinical trials with
remyelination therapies.
The ability to accurately measure the rate of myelin forma-
tion and breakdown may be used to measure pharmacologi-
cal effects of novel drugs designed to increase remyelination,
thereby facilitating the development of a more effective treat-
ment for patients with multiple sclerosis or other demyelinat-
ing diseases/disorders.
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